Filing Flows › Comparisons › ABUS vs PRPH
Arbutus Biopharma vs ProPhase Labs: ABUS and PRPH compared
Arbutus Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $1.0M for ProPhase Labs (Q2 2026). ProPhase Labs is growing faster (-19% against -91% a year earlier). ProPhase Labs is more profitable, with an operating margin of -261.6% against -588.2%.
Where the money goes: ABUS and PRPH
Arbutus Biopharma (ABUS) · Q2 2026
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
ProPhase Labs (PRPH) · Q2 2026
ProPhase Labs, Q2 2026: revenue $1.0M (-19% year over year), operating margin -261.6%, net loss $3.1M, operating cash flow −$78K. The chart follows the revenue to costs, profit and cash.
| Arbutus Biopharma (ABUS) | ProPhase Labs (PRPH) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | -91% | -19% |
| Operating margin | -588.2% | -261.6% |
| Net earnings | −$5.1M | −$3.1M |
| Net margin | -507.2% | -301.8% |
| Operating cash flow | −$6.0M | −$78K |
Where the revenue comes from
Arbutus Biopharma
- Revenue from collaborations and licenses: $632K (62%)
- Collaborations and licenses: $202K (20%)
- Non-cash royalty revenue: $180K (18%)
Questions
Which is bigger, Arbutus Biopharma or ProPhase Labs?
Arbutus Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $1.0M for ProPhase Labs (Q2 2026).
Is Arbutus Biopharma or ProPhase Labs growing faster?
ProPhase Labs is growing faster (-19% against -91% a year earlier).
Which is more profitable, Arbutus Biopharma or ProPhase Labs?
ProPhase Labs is more profitable, with an operating margin of -261.6% against -588.2%.
More: Arbutus Biopharma earnings · how Arbutus Biopharma makes money · ProPhase Labs earnings · how ProPhase Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.